Navicixizumab  (Synonyms: OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab))

Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel.html" class="link-product" target="_blank"> Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer^[1][2][3].

IC50: hVEGF (0.36 nM), mVEGF (25.5 nM), hDLL4 (1.3 nM)

Navicixizumab (0-100 μM) reduces proliferation of human endothelial cells in the presence of hVEGF^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Navicixizumab (15 mg/kg, once a week for 4 weeks) inhibits colon xenograft tumor growth^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1638338-43-8

[Navicixizumab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Fu S, et al. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 Aug 10;40(23):2568-2577.  [Content Brief]

  [2]. Perez-Fidalgo JA, et al. NOTCH signalling in ovarian cancer angiogenesis. Ann Transl Med. 2020 Dec;8(24):1705.  [Content Brief]

  [3]. Wan-Ching Yen, et al. Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency. Mol Cancer Ther (2015) 14 (12_Supplement_2): C164.